ES2258722T3 - Tiofenos sustituidos, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que los contiene. - Google Patents

Tiofenos sustituidos, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que los contiene.

Info

Publication number
ES2258722T3
ES2258722T3 ES03740148T ES03740148T ES2258722T3 ES 2258722 T3 ES2258722 T3 ES 2258722T3 ES 03740148 T ES03740148 T ES 03740148T ES 03740148 T ES03740148 T ES 03740148T ES 2258722 T3 ES2258722 T3 ES 2258722T3
Authority
ES
Spain
Prior art keywords
methyl
chloro
hydrogen
diseases
benzimidazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03740148T
Other languages
English (en)
Spanish (es)
Inventor
Hans-Jochen Lang
Uwe Heinelt
Armin Hofmeister
Klaus Wirth
Michael Gekle
Markus Bleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of ES2258722T3 publication Critical patent/ES2258722T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES03740148T 2002-06-04 2003-05-26 Tiofenos sustituidos, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que los contiene. Expired - Lifetime ES2258722T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10224892 2002-06-04
DE10224892A DE10224892A1 (de) 2002-06-04 2002-06-04 Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
ES2258722T3 true ES2258722T3 (es) 2006-09-01

Family

ID=29557542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03740148T Expired - Lifetime ES2258722T3 (es) 2002-06-04 2003-05-26 Tiofenos sustituidos, procedimiento para su preparacion, su uso como medicamento o agente diagnostico, asi como medicamento que los contiene.

Country Status (32)

Country Link
EP (1) EP1513834B1 (cg-RX-API-DMAC7.html)
JP (1) JP4511924B2 (cg-RX-API-DMAC7.html)
KR (1) KR101087966B1 (cg-RX-API-DMAC7.html)
CN (1) CN1324024C (cg-RX-API-DMAC7.html)
AR (1) AR040239A1 (cg-RX-API-DMAC7.html)
AT (1) ATE320425T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003273553B2 (cg-RX-API-DMAC7.html)
BR (1) BR0311548A (cg-RX-API-DMAC7.html)
CA (1) CA2488242C (cg-RX-API-DMAC7.html)
CR (1) CR7577A (cg-RX-API-DMAC7.html)
DE (2) DE10224892A1 (cg-RX-API-DMAC7.html)
DK (1) DK1513834T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045471A (cg-RX-API-DMAC7.html)
ES (1) ES2258722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20041153A2 (cg-RX-API-DMAC7.html)
IL (1) IL165519A (cg-RX-API-DMAC7.html)
MA (1) MA27204A1 (cg-RX-API-DMAC7.html)
ME (1) MEP27608A (cg-RX-API-DMAC7.html)
MX (1) MXPA04011986A (cg-RX-API-DMAC7.html)
MY (1) MY129832A (cg-RX-API-DMAC7.html)
NO (1) NO329351B1 (cg-RX-API-DMAC7.html)
OA (1) OA12827A (cg-RX-API-DMAC7.html)
PE (1) PE20040534A1 (cg-RX-API-DMAC7.html)
PL (1) PL372589A1 (cg-RX-API-DMAC7.html)
PT (1) PT1513834E (cg-RX-API-DMAC7.html)
RS (1) RS51141B (cg-RX-API-DMAC7.html)
RU (1) RU2315766C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN04240A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283675B (cg-RX-API-DMAC7.html)
UA (1) UA77551C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003101984A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409095B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242560A1 (en) 2003-05-22 2004-12-02 Aventis Pharma Deutschland Gmbh Process for synthesizing heterocyclic compounds
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
EP1640361B9 (en) 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst
JP2010507664A (ja) * 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
EP2342178B1 (en) 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
RU2373929C1 (ru) * 2008-11-11 2009-11-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN120112529B (zh) * 2023-09-28 2026-01-06 四川大学华西医院 一种含吡啶的化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
BR6915362D0 (pt) * 1969-08-16 1973-01-04 Hoechst Ag Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos
DE2830279A1 (de) * 1978-07-10 1980-01-31 Boehringer Sohn Ingelheim 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
DE19921883A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.

Also Published As

Publication number Publication date
JP4511924B2 (ja) 2010-07-28
RS103804A (sr) 2006-12-15
DK1513834T3 (da) 2006-07-17
PL372589A1 (en) 2005-07-25
RU2315766C2 (ru) 2008-01-27
KR101087966B1 (ko) 2011-12-01
KR20050005532A (ko) 2005-01-13
IL165519A (en) 2010-05-31
BR0311548A (pt) 2005-04-12
DE50302673D1 (de) 2006-05-11
RU2004138812A (ru) 2005-07-20
EP1513834A1 (de) 2005-03-16
MEP27608A (en) 2010-06-10
CA2488242C (en) 2011-08-02
CN1324024C (zh) 2007-07-04
CN1659163A (zh) 2005-08-24
OA12827A (en) 2006-07-11
IL165519A0 (en) 2006-01-15
MXPA04011986A (es) 2005-03-07
RS51141B (sr) 2010-10-31
WO2003101984A1 (de) 2003-12-11
JP2005533038A (ja) 2005-11-04
AR040239A1 (es) 2005-03-23
HK1076460A1 (en) 2006-01-20
PE20040534A1 (es) 2004-10-25
CR7577A (es) 2005-06-16
NO329351B1 (no) 2010-10-04
ZA200409095B (en) 2005-05-10
ECSP045471A (es) 2005-01-28
MA27204A1 (fr) 2005-01-03
CA2488242A1 (en) 2003-12-11
NO20045504L (no) 2005-01-25
EP1513834B1 (de) 2006-03-15
AU2003273553B2 (en) 2008-12-04
UA77551C2 (en) 2006-12-15
TW200406409A (en) 2004-05-01
MY129832A (en) 2007-05-31
PT1513834E (pt) 2006-06-30
DE10224892A1 (de) 2003-12-18
TNSN04240A1 (en) 2007-03-12
HRP20041153A2 (en) 2005-06-30
ATE320425T1 (de) 2006-04-15
TWI283675B (en) 2007-07-11
AU2003273553A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
US7763643B2 (en) Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
RU2272031C2 (ru) Замещенные 2-анилино-бензимидазолы, их применение в качестве ингибиторов na+/h+-обмена, а также содержащее их лекарственное средство
EP1794128A1 (de) Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament
RU2315766C2 (ru) Замещенные тиофены, их применение в качестве лекарственного или диагностического средства и содержащее их лекарственное средство
ES2470980T3 (es) 4-feniltetrahidroisoquinolinas sustituidas, procedimiento para producirlas, su uso como medicamento, as� como medicamento que las contiene
ES2543345T3 (es) 2-amino-4-fenil-dihidroquinolinas sustituidas, procedimiento para su preparación, su uso como medicamento así como medicamento que las contiene
JP5249918B2 (ja) 置換された1−アミノ−4−フェニル−ジヒドロイソキノリン、それらの製造法、それらの薬剤としての使用、およびそれらを含有する薬剤
US7179830B2 (en) Substituted thienoimidazoles useful for disease treatment and prevention
ES2304634T3 (es) Procedimiento para la preparacion de derivados de (3-oxo-2,3-dihidro-1h-isoindol-1-il)-acetilguanidina.
ES2275945T3 (es) Imidazolidinas sustituidas, procedimiento para su preparacion, su uso como medicamento o agente de diagnostico, asi como medicamento que las contiene.
NZ536970A (en) Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same